IS12. Antidepressant Treatments You May Not Know About, But Should. . . Supported by Organon Inc.
A. The Next Generation of Antidepressants: What Is in the Pipeline? Rajinder A. Judge, M.D.
B. Alternative Medications for Depression Andrew A. Nierenberg, M.D.
C. Evidence-Based Psychotherapy for Depression: Principles and Practice Timothy J. Petersen, Ph.D.
D. Device-Based Treatments for Depression A. John Rush, M.D.
E. The Future of Treatment Matching in Depression Steven P. Roose, M.D.
IS13. Broadening the Horizon of Atypical Antipsychotic Applications Supported by AstraZeneca Pharmaceuticals
A. Atypical Antipsychotics in Anxiety and PTSD Mark B. Hamner, M.D.
B. Atypical Antipsychotics Treatment of Substance Abuse E. Sherwood Brown, M.D.
C. Role of Atypicals in the Treatment of Pediatric Psychotic Disorders and Common Comorbidities Melissa P. DelBello, M.D.
D. Atypicals in the Treatment of Anorexia Nervosa Walter H. Kaye, M.D.
E. Atypicals in BPD S. Charles Schulz, M.D.
IS14. The Many Faces of Anxiety: Origins, Pathogenesis, and Management Supported by Pfizer Inc.
A. Generalized Anxiety, Social Anxiety, and Panic Disorder: New Views on Validity and Nosology Risa B. Weisberg, Ph.D.
B. Origins and Pathogenesis of Anxiety Symptoms and Syndromes Dennis S. Charney, M.D.
C. Pharmacologic Approaches for Panic Disorder David V. Sheehan, M.D.
D. GAD: Current Opinions and Future Options Linda L. Carpenter, M.D.
IS15. From Pathology to Practice: Evolving Therapeutic Strategies for Alzheimer’s Disease Supported by Forest Laboratories Inc.
A. Synaptic Dysfunction and Neurodegeneration in Alzheimer’s Disease Gary L. Wenk, Ph.D.
B. Alzheimer’s Disease Update: New Targets, New Options Jacobo E. Mintzer, M.D.
C. Alzheimer’s Disease and Vascular Dementia: Where Is the Overlap? John C. Morris, M.D.
D. Multicultural Issues in Addressing Barriers to Diagnosis and Treatment Warachal E. Faison, M.D.
E. A Rational Approach to Combination Treatment Mary Sano, Ph.D.
IS16. Broadening Horizons: Advances in Understanding the Etiology, Effects, and Treatment of Anxiety Disorders Supported by UCB Pharma Inc.
A. Anxiety on the Upswing? A Public Health Perspective Murray B. Stein, M.D.
B. Neural Substrates of Stress, Anxiety, and Early Adversity: Neurotrophic Perspectives Jeremy D. Coplan, M.D.
C. Gender and Anxiety Disorders: Impact and Treatment Implications Naomi M. Simon, M.D.
D. Treating Anxiety: Current Therapies and Beyond Mark H. Pollack, M.D.
E. Treatment Works: Now What Do We Do? Strategies to Enhance Treatment Adherence Michael W. Otto, Ph.D.
IS17. The Hidden Faces of Anxiety Supported by GlaxoSmithKline
A. The Somatic Face of Anxiety Prakash S. Masand, M.D.
B. Anxiety in Men and Women: Two Faces of the Same Coin Kimberly A. Yonkers, M.D.
C. The Many Faces of Anxiety: Understanding Cultural and Ethnic Variation in Psychiatric Illness Geetha Jayaram, M.D.
D. Facets of Psychiatric Illness in the Elderly Warren D. Taylor, M.D.
IS18. Targeting Executive Dysfunctions for Treatment Supported by Cephalon Inc.
A. Executive Function: Circuits and Symptoms Stephen M. Stahl, M.D.
B. Addressing the Neurobiological Dysfunctions of Deficit Syndrome Rona Hu, M.D.
C. Late-Life Depression of Executive Dysfunction: Novel Treatment Development George S. Alexopoulos, M.D.
D. Cognitive and Executive Dysfunction in Major Depression Charles DeBattista, M.D.
E. Addressing Executive Dysfunctions in ADHD James M. Swanson, M.D.
IS19. The Treacherous Triad for Depression Supported by Wyeth Pharmaceuticals
A. Underdetection and Inadequate Treatment of Physical Symptoms of Depression: The Real Barriers to Remission Kurt Kroenke, M.D.
B. Neurochemical Systems Interfacing Physical and Emotional Stressors Jon-Kar Zubieta, M.D.
C. Stress Effects on the Hippocampus: Relevance to Depression Bruce S. McEwen, Ph.D.
D. Gender Considerations in the Treatment of Physical Symptoms of Depression Vivien K. Burt, M.D.
E. Best Practices for Achieving Remission in Depression With Physical Symptoms: Current and Future Trends John F. Greden, M.D.
IS20. Beyond 5HT: New Treatments for Depression Supported by Merck and Co. Inc.
A. Combining Treatment to Enhance SSRI Response Jack M. Gorman, M.D.
B. What to Do for SSRI Nonresponders Michael E. Thase, M.D.
C. The Relationship Between Substance P, 5HT, and Other Neurotransmitter Systems Linda L. Carpenter, M.D.
D. Substance P Antagonists: Mechanism of Action and Clinical Implications K. Ranga R. Krishnan, M.D.
IS21. Are All Atypical Antipsychotics Equal for Treatment of Cognitive and Affective Symptoms in Schizophrenia? Supported by Pfizer Inc.
A. Schizophrenia: From Circuits to Symptoms Stephen M. Stahl, M.D.
B. Effect of Atypical Antipsychotic Drugs on Cognition and Negative Symptoms Herbert Y. Meltzer, M.D.
C. Optimal Health Outcomes in Schizophrenia Jonathan M. Meyer, M.D.
D. Maximizing Function in Patients With Schizophrenia Lili Kopala, M.D.
IS22. Combination Therapy: New Strategies in the Management of Severe Mental Disorders Supported by Abbott Laboratories
A. Rational Combination Therapy Versus Irrational Polypharmacy Susan L. McElroy, M.D.
B. Combination Treatment for Acute Mania Gary S. Sachs, M.D.
C. Management of Bipolar Depression: Combination Therapy Versus Monotherapy Robert M.A. Hirschfeld, M.D.
D. Managing Bipolar Disorder in Children and Adolescents Karen D. Wagner, M.D.
E. Evidence for the Mechanisms and Efficacy of Anticonvulsants in the Treatment of Schizophrenia Carol A. Tamminga, M.D.
IS23. Unmasking Bipolar Disorder: Overcoming the Barriers to Treatment Success Supported by Janssen Pharmaceutica and Research Foundation
A. Bipolar Disorder: A National Health Concern Roger S. McIntyre, M.D.
B. Redefining Mood-Stabilizing Agents: Improved Treatment Options for Bipolar Disorder S. Nassir Ghaemi, M.D.
C. Safety Considerations in Treating the Bipolar Disorder Patient Prakash S. Masand, M.D.
D. The Essential Role of Psychotherapy in Managing Bipolar Disorder Michael W. Otto, Ph.D.
L1. Infanticide: The Hope of Prevention and the Promise of Saved Lives Margaret G. Spinelli, M.D., AAPL/APA’s Manfred S. Guttmacher Award Lecture
IS24. Recovering From Schizophrenia: How Treatment Can Improve Outcomes and Prevent Chronicity Supported by Eli Lilly and Company
A. Laboratory and Imaging Aids to Diagnosis and Assessment of Schizophrenia Aysenil Belger, Ph.D.
B. Treating First-Episode Schizophrenia: Differential Effects of Atypical and Typical Antipsychotics on Brain Pathomorphology Jeffrey A. Lieberman, M.D.
C. Approaches to Improved Maintenance Treatment and Relapse Prevention T. Scott Stroup, M.D.
D. Psychiatric Rehabilitation Robert E. Drake, M.D.
E. Cognitive Improvement and Therapeutic Alliance Richard S.E. Keefe, Ph.D.
IS25. Novel Intervention Strategies Across the Spectrum of Dementia: Real Patients and Real Outcomes Supported by Eisai Inc.
A. Identifying Early Dementia: Mild Cognitive Impairment and Early-Stage Alzheimer’s Disease P. Murali Doraiswamy, M.D.
B. Identifying and Treating Early Dementia: Case Studies Daniel D. Christensen, M.D.
C. Exploring Vascular Dementia: Diagnosis, Treatment, and Behavior Helen Lavretsky, M.D.
D. Exploring Differences Between Vascular Dementia and Alzheimer’s Disease: Case Studies Stephen P. Salloway, M.D.
E. Defining and Achieving Positive Outcomes in Dementia Pharmacotherapy David Geldmacher, M.D.
F. Alzheimer’s Disease Prevention: Strategies for Improving Brain and Memory Fitness Gary W. Small, M.D.
IS26. Effective Long-Term Management of Schizophrenia: Real-World Considerations Supported by Bristol-Myers Squibb Company
A. The Evolution of Antipsychotic Agents: A Mechanism-Based Review Anissa Abi-Dargham, M.D.
B. Optimizing the Long-Term Effectiveness of Antipsychotic Therapy Stephen R. Marder, M.D.
C. Managing Patients With Treatment-Resistant Schizophrenia John M. Kane, M.D.
D. What Is Effectiveness With Antipsychotic Medications? Peter J. Weiden, M.D.
IS27. Moderators and Mediators of Antidepressant Response Supported by Forest Laboratories Inc.
A. Moderators and Mediators of Treatment Effects in Antidepressant Trials Philip Lavori, Ph.D.
B. Gender as a Moderator of Antidepressant Response Susan G. Kornstein, M.D.
C. Placebo, Comparator, or Open Treatment? Design Counts Steven P. Roose, M.D.
D. Duration of Antidepressant Treatment: How Long Is Long Enough? How Long Is Too Long? Harold A. Sackeim, Ph.D.
E. Moving the Goal Posts: Treating Beyond Response to Remission David J. Kupfer, M.D.
IS28. Beyond Sleep Onset: New Perspectives on the Treatment of Insomnia Supported by Sepracor Inc.
A. Prevalence and Impact of Insomnia: Treating the Entire Insomnia Syndrome Mugdha E. Thakur, M.D.
B. Differential Diagnosis of Insomnia and Comorbid Conditions: Importance of Sleep History Jed E. Black, M.D.
C. Measures of Treatment Efficacy Thomas Roth, Ph.D.
D. Overview of Insomnia Treatment Andrew D. Krystal, M.D.
IS29. Psychopharmacology and Reproductive Transitions: Impact of Psychotropic Medications and Sex Hormones on Brain Functioning, Weight, and Reproductive Safety Supported by GlaxoSmithKline
A. Labeling Products for Use in Pregnancy: Moving Forward Sandra L. Kweder, M.D.
B. Weight Gain, Psychotropic Medications, and Gender: Potential Pharmacologic Strategies Barbara L. Gracious, M.D.
C. Testosterone Decline in the Aging Male: Does Andropause Exist? Stuart N. Seidman, M.D.
D. Perimenopause-Related Mood Disturbance: An Update on Risk Factors and Novel Treatment Strategies Available Claudio N. Soares, M.D.
E. Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women’s Health Initiative Memory Study Updates Sally A. Shumaker, Ph.D.
IS30. Choosing the Right Dose of Atypical Antipsychotics: Art or Science? Supported by AstraZeneca Pharmaceuticals
A. Dosing With Atypicals: Receptor Occupancy as a Guide to Titration and Maintenance Shitij Kapur, M.D.
B. Acute Stabilization of Psychosis: Options and Approaches K.N. Roy Chengappa, M.D.
C. Strategies for Maintenance Pharmacotherapy: High, Low, or Switch? Peter F. Buckley, M.D.
D. Administration of Atypicals in Bipolar Disorder Claudia F. Baldassano, M.D.
E. Is Polypharmacy the Result of Confused Dosing Strategies for Atypical Antipsychotics? Alexander L. Miller, M.D. ▪